

University of Strathclyde

Strathclyde Institute of Pharmacy and Biomedical Science

The role of IL-4R α signaling during *Toxoplasma gondii*
infection

by

Thabang Mokgethi

A thesis submitted in fulfillment of the requirements for
the degree of Doctor of Philosophy

2010

This thesis is the result of the author's original research.

It has been composed by the author and has not been previously submitted for examination which has led to the award of a degree.

The copyright of this thesis belongs to the author under the terms of the United Kingdom Copyright Acts as qualified by University of Strathclyde Regulation 3.50. Due acknowledgement must always be made of the use of any material contained in, or derived from, this thesis.

Signed:

Date:

ACKNOWLEDGEMENTS

First I would like to thank Professor Frank Brombacher and Professor James Alexander for offering me the opportunity to do a PhD here. To my primary supervisor Professor James Alexander, thank you for the constant support and guidance throughout the past few years. It has been a great learning curve. I would also like to thank my second supervisor Dr Craig Roberts for his support throughout my time here, I have acquired a lot of knowledge and skills under your supervision. Dr Fiona Henriques, thank you for your support and contribution to my work. I would also like to thank Dr Fiona Roberts for her contribution with the histology. I am very thankful for the technical assistance from the staff at the BPU, Gordon, Carol, Allan, George, thank you so much. Mrs Adrienne McGachy, thank you for always being your wonderful self and keeping my morale up. I cannot thank you enough for always being available to help with those T-cell assays! I would also like to thank my lab mates, past and present, who I have learnt a lot from and have been a pleasure to work with: Leigh, Emma, Fiona, Caroline, Sara, Karen, Selina, Chesney and everyone else in the lab. I would also like to thank Roderick Williams for giving advice and some much needed words of wisdom. Lastly, this would not have been possible without the support of my family. My mom and dad, SiPhuti and Daddy, your unconditional love and unwavering support are what kept me going. *Ga ke gola ke batla go tshwana le lona. Ke leboga Modimo ka go ntlhopela lona.* Thank you to the rest of my family and friends, my sister, uncles and aunts for being there for me. Masego thanks for always being there to listen. I'm blessed to have you all in my life. SiPhuti le Daddy, this is for you, for being my absolute rock stars. *Ke a leboga.*

ABSTRACT

A type-1 cytokine response is critical for protective immunity against *Toxoplasma gondii* infection. Nevertheless, a persistent overproduction of type-1 cytokines can be detrimental to the host and cause fatal immunopathology. The extent to which type-2 cytokines can modulate the disease exacerbating versus protective responses remains largely unresolved. Previous studies have shown that IL-4 and IL-4R α deficient BALB/c mice are highly susceptible to *T. gondii* infection. IL-4 can modulate type-1 inflammatory responses by counter-regulating the effects of IFN- γ on CD4⁺ T cells and/or macrophages. In order to analyze the protective mechanism(s) and functional target(s) of IL-4 during *T. gondii* infection the outcomes of *T. gondii* infection in macrophage/neutrophil specific IL-4R α ^{-/-} BALB/c (LysM^{cre}IL-4R α ^{-/lox}) mice, CD4⁺ T cell specific IL-4R α ^{-/-} (Lck^{cre}IL-4R α ^{-/lox}) mice, CD4⁺CD8⁺T cell specific IL-4R α ^{-/-} (NLck^{cre}IL-4R α ^{-/lox}) mice and their wild type (IL-4R α ^{-/lox}) littermates as well as global IL-4R α ^{-/-} mice were compared. Overall female mice were more susceptible to infection compared with male mice as measured by mortality and this was associated with delayed parasite specific type-1 cytokine responses. *T. gondii* infection in LysM^{cre}IL-4R α ^{-/lox} mice resulted in an augmented type-1 cytokine response and excessive lung pathology which caused increased mortality which was similar to global IL-4R α ^{-/-} mice and more severe than IL-4R α intact (WT) mice. On the other hand Lck^{cre}IL-4R α ^{-/lox} were relatively resistant to infection and had a similar phenotype to WT mice, whilst NLck^{cre}IL-4R α ^{-/lox} mice exhibited increased susceptibility during the chronic phase of

infection. Splenocytes from NLck^{cre}IL-4R α ^{-/lox} mice but not Lck^{cre}IL-4R α ^{-/lox} had impaired parasite-specific IFN- γ production. *T. gondii* was demonstrated to induce various elements of alternative macrophage activation independently of IL-4R α while RT-PCR analysis revealed that markers of alternative macrophage activation YM1, Arginase1 and FIZZ1 may contribute to disease protective and/or exacerbative processes during infection. Collectively, these findings illustrate the multifaceted innate and adaptive IL-4/IL-13-mediated responses employed to influence *T. gondii* infection.

TABLE OF CONTENTS

TITLE PAGE.....	I
COPYRIGHT.....	II
ACKNOWLEDGEMENTS.....	III
ABSTRACT.....	IV
TABLE OF CONTENTS.....	VI
LIST OF FIGURES.....	XII
LIST OF TABLES.....	XVI
LIST OF ABBREVIATIONS.....	XVII

CHAPTER 1

GENERAL INTRODUCTION

1. INTRODUCTION.....	1
1.1. History and taxonomy of <i>Toxoplasma gondii</i>	2
1.2. Lifecycle	2
1.3. Pathogenesis	7
1.4. Treatment and prevention strategies.....	9
1.5. Immunology.....	11
1.5.1. Immunity to <i>T. gondii</i> infection.....	11
1.5.2. Cell-mediated immune response.....	12
1.5.3. The role of cytokines during <i>T. gondii</i> infection.....	23
1.5.3.1. Type-1 cytokines.....	23
1.5.3.2. Type-2 cytokines.....	24

1.5.3.3. Novel IFN- γ related pathways of <i>T. gondii</i> growth inhibition.....	30
1.6. Macrophage activation.....	36
1.6.1. Classical macrophage activation.....	36
1.6.2. Alternative macrophage activation.....	37
1.7. Aims and objectives.....	42
CHAPTER 2.....	44
MATERIALS AND METHODS	
2. Methods.....	45
2.1. Mice.....	45
2.1.1. Genotyping.....	45
2.1.2. <i>T. gondii</i> infections.....	49
2.2. Preparation of <i>Toxoplasma</i> lysate antigen (TLA).....	49
2.3. Splenocyte stimulation assays.....	50
2.4. Serum preparation for cytokine analysis.....	51
2.4.1. Measurement of NO by Griess method.....	51
2.4.2. Cytokine analysis by ELISA.....	52
2.4.3. Antibody ELISA.....	53
2.5. Histopathological analysis of mouse tissues.....	54
2.6. RNA extractions.....	55
2.6.1. cDNA synthesis.....	56
2.6.2. Quantitative RT-PCR.....	57

2.6.3. Parasite quantification using qRT-PCR.....	63
2.7. Statistical analysis.....	63
CHAPTER 3.....	64
THE ROLE OF IL-4Rα SIGNALING IN MACROPHAGES/NEUTROPHILS	
DURING <i>T. GONDII</i> INFECTION	
3. Abstract.....	65
3.1. Introduction.....	67
3.2. Results.....	70
3.2.1. Survival studies during <i>T. gondii</i> infection.....	70
3.2.2. Histopathological analysis during acute <i>T.gondii</i> infection	72
3.2.3. Serum cytokine levels in <i>T. gondii</i> infected mice.....	76
3.2.4. Analyses of <i>T. gondii</i> -specific splenocyte cytokine production.....	78
3.2.5. Analyses of cytokine mRNA transcript expression and parasite	
burden.....	81
3.3. Discussion.....	87
CHAPTER 4.....	93
THE ROLE OF IL-4Rα SIGNALING THROUGH CD4+ T-CELLS DURING <i>T.</i>	
<i>GONDII</i> INFECTION	
4. Abstract.....	94
4.1. Introduction.....	95

4.2. Results.....	98
4.2.1. Survival studies during <i>T. gondii</i> infection.....	98
4.2.2. Bodyweights of mice during <i>T. gondii</i> infection.....	100
4.2.3. Histopathological analysis of tissues during acute <i>T. gondii</i> infection.....	104
4.2.4. Serum cytokine levels in <i>T. gondii</i> infected male and female mice.....	115
4.2.5. Analysis of splenocyte recall responses.....	121
4.2.6. Measurement of cytokine and parasite mRNA transcript expression.....	134
4.2.7. Histopathological analysis of mouse tissues during chronic <i>T. gondii</i> infection.....	148
4.3. Discussion.....	153
CHAPTER 5.....	165
THE ROLE OF IL-4Rα SIGNALING IN CD4+ AND CD8+ T-CELLS DURING <i>T.</i> <i>GONDII</i> INFECTION	
Abstract.....	166
5. Introduction.....	167
5.1. Results.....	170
5.1.1. Survival of <i>T. gondii</i> infected male and female mice.....	170
5.1.2. Bodyweights.....	172

5.1.3. Histopathological analysis.....	175
5.1.4. Serum cytokine level analyses during acute infection.....	182
5.1.5. Splenocyte recall responses during acute <i>T. gondii</i> infection.....	185
5.1.6. Expression of cytokine and parasite mRNA transcripts.....	193
5.1.7. Histopathological analysis of tissues during chronic infection.....	204
5.1.8. Systemic cytokine and antibody production during chronic infection.....	216
5.1.9. Discussion.....	220
 CHAPTER 6.....	229
<i>IN VIVO</i> STUDIES TO DETERMINE THE ROLE OF <i>T. GONDII</i> IN INDUCTION OF ALTERNATIVELY ACTIVATED MACROPHAGES	
6. Abstract.....	230
6.1. Introduction.....	231
6.2. Methods.....	235
6.2.1. Experimental animals and infection.....	235
6.2.2. BAL technique and macrophage isolation.....	235
6.2.3. RNA extraction.....	236
6.3. Results.....	237
6.4. Discussion.....	242

CHAPTER 7.....	246
7. GENERAL DISCUSSION.....	247
REFERENCES.....	262
APPENDIX.....	292

FIGURES

1. <i>T. gondii</i> lifecycle	6
2. <i>T. gondii</i> gut immunology	19
3. Schematic diagram of type-1/type-2 cytokine mediated immune responses	21
4. Schematic diagram of the IL-4/IL-13 signaling pathway	29
5. Classical and alternative macrophage activation pathways	40
3.1 Survival curve of female $LysM^{cre}IL-4R\alpha^{-/lox}$ and control mice	71
3.2 Histopathological analysis in female mice	73
3.2B Lung histopathology photographs	74
3.3 Serum cytokine in female mice, IFN- γ , IL-12, IL-10	77
3.4 Splenocyte IFN- γ production in $LysM^{cre}IL-4R\alpha^{-/lox}$ and control mice.....	79
3.5 Splenocyte IL-10 production in $LysM^{cre}IL-4R\alpha^{-/lox}$ and control mice	80
3.6 Lung IFN- γ , IL-12, NOS2 mRNA in $LysM^{cre}IL-4R\alpha^{-/lox}$ and control mice.....	82
3.7 Alternative macrophage activation markers mRNA expression FIZZ1, YM1, Arginase1 in $LysM^{cre}IL-4R\alpha^{-/lox}$ and control mice.....	83
3.8 Lung mRNA transcript expression IDO, LRG47 and Igtp GTPase in $LysM^{cre}IL-4R\alpha^{-/lox}$ and control mice.....	85
3.9 Parasite burden in the lungs of $LysM^{cre}IL-4R\alpha^{-/lox}$ and control mice.....	86
4.1 Survival curve for male and female $Lck^{cre}IL-4R\alpha^{-/lox}$ mice with control mice	99

4.2 Bodyweights of male and female Lck ^{cre} IL-4R α ^{-/lox} mice with control mice	102
4.1 Day 9 lung and liver histopathology of male Lck ^{cre} IL-4R α ^{-/lox} mice and control mice	107
4.1A Males day 9, photographs of lung pathology	108
4.2 Females day 9 Lck ^{cre} IL-4R α ^{-/lox} mice and control mice, lung and liver histopathology	112
4.3 Females day 12 Lck ^{cre} IL-4R α ^{-/lox} mice and control mice, lung and liver histopathology	114
4.4 Serum IFN- γ in male and female mice	118
4.5 Serum IL-12 in male and female mice	119
4.6 Serum IL-4 and IL-10 in male and female mice	120
4.7 Splenocyte NO in male and female mice	123
4.8 Splenocyte IFN- γ in male and female mice	126
4.9 Splenocyte IL-12 in male and female mice	129
4.10 Splenocyte IL-4 in male and female mice	132
4.11 Splenocyte IL-10 in male and female mice	133
4.12 Lung IFN- γ and IL-12 mRNA transcript expression	137
4.13 Lung NOS2 and Arginase1 mRNA transcript expression	140
4.14 Lung YM1 and FIZZ1 mRNA transcript expression	141
4.15 Lung LRG47 and Igtp GTPase transcript expression	145
4.16 Lung IDO mRNA transcript expression	146

4.17 Parasite mRNA transcript burden in the lung	147
4.18 Day 35 lung histopathology in male Lck ^{cre} IL-4R α ^{-lox} and control mice	150
4.18A,B Day 35 lung histopathology photographs.....	151
4.19 Day 35 brain histopathology in male Lck ^{cre} IL-4R α ^{-lox} and control mice.....	152
5.1 Survival curves for male and female NLck ^{cre} IL-4R α ^{-lox} and control mice.....	171
5.2 Bodyweights for male and female NLck ^{cre} IL-4R α ^{-lox} and control mice.....	174
5.3 Male day 9 lung and liver histopathology, NLck ^{cre} IL-4R α ^{-lox} and control mice	177
5.3A Male day 9 lung pathology photographs.....	178
5.4 Female day 9 lung and liver histopathology, NLck ^{cre} IL-4R α ^{-lox} and control mice	179
5.5 Female day 12 lung and liver histopathology, NLck ^{cre} IL-4R α ^{-lox} and control mice	180
5.5D Female day 12 liver pathology photographs.....	181
5.6 Serum IFN- γ and IL-12p40 male and female mice.....	184
5.7 Splenocyte NO male and female mice.....	188
5.8 Splenocyte IFN- γ male and female mice.....	189
5.9 Splenocyte IL-12 male and female mice.....	190
5.10 Splenocyte IL-4 male and female mice.....	191
5.11 Splenocyte IL-10 male and female mice.....	192
5.12 Lung IFN- γ and IL-12 mRNA transcript expression	195
5.13 Lung NOS2 and Arginase1 mRNA transcript expression.....	199

5.14 Lung YM1 and FIZZ1 mRNA transcript expression.....	200
5.15 Lung IDO mRNA transcript expression.....	201
5.16 Lung LRG47 and Igtp GTPase mRNA expression.....	202
5.17 Parasite mRNA transcript burden in the lungs.....	203
5.18 Day 35 lung and liver histopathology in male mice.....	206
5.18A Day 35 male lung pathology photographs.....	207
5.19 Day 35 brain histopathology in male mice.....	208
5.20 Day 35 lung and liver histopathology in female mice.....	210
5.20C,D Day 35 female liver pathology photographs.....	211
5.21 Day 35 brain histopathology in female mice.....	213
5.21B Day 35 female brain pathology photographs.....	214
5.22 Serum IFN γ - and IL-12 day 35 male and female mice.....	218
5.23 <i>T. gondii</i> -specific IgG1 and IgG2a in male and female mice serum.....	219
6.1 BAL macrophage IL-12 and NOS2 mRNA transcript expression.....	239
6.2 BAL macrophage FIZZ1, YM1 and Arginase1 transcript expression.....	240
6.3 BAL macrophage parasite mRNA transcript burden.....	241

TABLES

1. Primer pairs and sequences for genotyping PCR.....	47
1.1 Genotyping PCR programme.....	48
2. Primer pairs and sequences for quantitative RT-PCR.....	59
2.1 Quantitative RT-PCR programme.....	62
4.1 Lung and liver histopathology scores for male mice 9 days post-infection with <i>T. gondii</i>	106
4.2 Lung and liver histopathology scores for female mice 9 days post-infection with <i>T. gondii</i>	111
4.3 Lung and liver histopathology scores for female mice 12 days post-infection with <i>T. gondii</i>	113
5. Summary of IL-4-deficient mouse models and <i>T. gondii</i> infection.....	260

ABBREVIATIONS

Arg1	Arginase1
BAL	Bronchoalveolar lavage
BSA	Bovine Serum Albumin
CD	Cluster of Differentiation
cDNA	Complementary Deoxyribonucleic Acid
CNS	Central Nervous System
ConA	Concavalin A
DC	Dendritic cell
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
FIZZ1	Found in inflammatory zone-1
GAPDH	Glyceraldehydes-3-phosphate dehydrogenase
HP	High Power
IDO	Indoleamine 2,3-dioxygenase
IEL	Intraepithelial cells
IFN-	Interferon
Ig	Immunoglobulin
IL	Interleukin
IL-4R	Interleukin-4 Receptor
iNOS	inducible Nitric oxide synthase
I.P	Intraperitoneal

kDA	Kilo Daltons
KO	Knock-out
LP	Low Power
LPS	Lipopolysaccharide
MHC	Major Histocompatibility Complex
MIF	Macrophage migration Inhibitory Factor
mRNA	Messenger Ribonucleic Acid
MyD88	Myeloid Differentiation Factor 88
MØ	Macrophage
NeMØ	Nematode elicited macrophages
NK	Natural Killer
NO	Nitric oxide
NOS2	Nitric oxide synthase-2
p	p-value
p.i	post infection
PMN	Polymorphonuclear leukocytes
PV	Parasitophorous Vacuole
PV cuffing	Perivascular cuffing
RELM- α	Resistin-like molecule- α
RNA	Ribonucleic acid
RNI	Reactive nitrogen intermediates
rpm	Revolutions per minute

SCID	Severe combined Immune Deficient
STAT	Signal transducer and activator of transcription
Tbp	TATA-box Binding protein
TE	Toxoplasmic encephalitis
TgCyst	<i>Toxoplasma gondii</i> Cyst matrix antigen
TGF	Tumour Growth Factor
Th	T helper
TLA	<i>Toxoplasma</i> Lysate Antigen
TLR	Toll-Like Receptor
TNF	Tumour Necrosis Factor
SEM	Standard Error of Mean